NCT06028607 ((PCD)) is a NA clinical trial of QD-27 in Primary Ciliary Dyskinesia, sponsored by University of Leeds.

Who is sponsoring NCT06028607?

NCT06028607 is sponsored by University of Leeds.

What drugs are being tested in NCT06028607?

Interventions in NCT06028607: QD-27.

What condition does NCT06028607 study?

NCT06028607 studies Primary Ciliary Dyskinesia.

Is NCT06028607 still recruiting?

NCT06028607 is currently completed. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT06028607: (PCD)

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of Consumption of Nutritional Supplementation in Primary Ciliary Dyskinesia

Completed NA Last updated 13 September 2023

What this trial tests

NA trial testing QD-27 in Primary Ciliary Dyskinesia in 15 participants. Completed in 28 February 2022.

Timeline

17 May 2021

Primary endpoint
29 November 2021

28 February 2022

Quick facts

Lead sponsor	University of Leeds
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	15
Start date	17 May 2021
Primary completion	29 November 2021
Estimated completion	28 February 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

QD-27

Conditions studied

Primary Ciliary Dyskinesia — all drugs for Primary Ciliary Dyskinesia →

Sponsor

University of Leeds

Who can join

17 and older, any sex, with Primary Ciliary Dyskinesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Feasibility study to understand and gain preliminary information on tolerability and palatability of an oral nutritional supplement gel in a clinical Primary Ciliary Dyskinesia population. To determine if dietary intake is affected by the consumption of the nutritional supplement. Explore possible future outcome measures that could be important in determining impact of this nutritional intervention on this patient group. Participants will be provided with the gel supplements and alongside will have other standard and non standard care measures assessed lung function (FEV1%) number of exacerbation's during study period vitamin D status Bio impedance analysis (BIA) skin-fold measures (e.g. Tricep Skin-fold (TSF) Mid upper arm circumference (MUAC) Handgrip strength (HGS) quality of life measures 6-minute walking tests. Hypothesis Patients with PCD can successfully consume 2 gel supplements per day for a period of 3 months with no effect on dietary intake.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Primary Ciliary Dyskinesia

Currently open trials in the same condition.

NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT07029594 — Thermal Spa Treatment and Improvement of Primary Ciliary Dyskinesia · NA · recruiting
NCT07288827 — Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia · NA · recruiting
NCT05685186 — A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults · active not recruiting
NCT04602481 — Living With Primary Ciliary Dyskinesia (Living With PCD) · recruiting

Other University of Leeds trials

Trials by the same sponsor.

NCT07488143 — AI-assisted Continuous Stratification in Neurorehabilitation of Stroke Using Personalized Digital Twins · NA · not yet recruiting
NCT07409363 — Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain · NA · not yet recruiting
NCT07247812 — tSCS in Children and Young People With HCP · NA · not yet recruiting
NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
NCT06240403 — Digoxin and Senolysis in Heart Failure and Diabetes Mellitus · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06028607 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leeds
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06028607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing